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Dried Chrysanthemum morifolium ﬂowers have traditionally been used in Korea for the treatment of insomnia. This study was
performed to investigate whether the ethanol extract of Chrysanthemum morifolium ﬂowers (EFC) enhances pentobarbital-
induced sleep behaviors. EFC prolonged sleep time induced by pentobarbital similar to muscimol, a GABAA receptors agonist.
EFC also increased sleep rate and sleep time when administrated with pentobarbital at a subhypnotic dosage. Both EFC
and pentobarbital increased chloride (Cl−) inﬂux in primary cultured cerebellar granule cells. EFC increased glutamic acid
decarboxylase (GAD) expression levels, but had no eﬀect on the expression of α1-, β2-, and γ2-subunits of the GABAA receptor
in the hippocampus of a mouse brain. This is in contrast to treatment with pentobarbital, which showed decreased α1-subunit
expression and no change in GAD expression. In conclusion, EFC augments pentobarbital-induced sleep behaviors; these eﬀects
may result from Cl− channel activation.
1.Introduction
The ﬂower of Chrysanthemum morifolium Ramat. (FC) has
been used in oriental countries for hundreds of years and
is widely consumed as a medicinal herbal tea [1, 2]. FC is
reportedtohavevariousbiologicalfeaturesincludingantiox-
idation [3], cardiovascular protection [4], antitumorgenesis
[5], and anti-inﬂammation [6]. Chrysanthemum species
have been shown to contain a wide variety of ﬂavonoids,
phenols, and phenolic acids [7]. Signiﬁcant amounts of
ﬂavonoidsandhydroxycinnamoylquinicacidsareconsidered
to be the biologically active components [4, 5, 8], and the
health beneﬁts of FC have been shown to be associated with
the ﬂavonoids [9]. In Korea, the dried FC in herbal tea
has traditionally been used for the treatment of insomnia
[3].
Insomnia symptoms are some of the most frequent sleep
complaints in the general population, with an estimated
prevalence varying from 10 to nearly 60%, depending in
part on the use of varying deﬁnitions and data-collection
methodologies [10]. Individuals reporting disturbed sleep
are more likely to report emotional distress and recurrent
health problems [11]. This is not surprising since it has
been shown that sleep deprivation has a great impact on
the everyday life of healthy subjects, aﬀecting alertness,
attention, concentration, cognitive abilities, memory, mood,
and pain.
A variety of modulators of GABA-transmission, includ-
ing neurosteroids, benzodiazepines, barbiturates, and GABA
agonists, have been investigated in both in vitro and in
vivo models. It is now well known that their eﬀects are
related to their binding to speciﬁc GABAA-receptor sub-
types. Muscimol and other GABAA receptor agonists that
potentiate Cl− inﬂux also cause potentiation of Cl− inﬂux
whenadministeredwithpentobarbitalorotheragonists[12].
The sedative and anticonvulsant eﬀects of diazepam and
zolpidem are primarily mediated by their interaction with
the α1-subunit [13]. Benzodiazepines and benzodiazepine-
like compounds are the most widely used hypnotics; they
primarily act to shorten sleep latency and enhance and
consolidate sleep. It was postulated that the hypnotic prop-
erties of benzodiazepines, that is, their capacity to shorten2 Evidence-Based Complementary and Alternative Medicine
sleep latency, to reduce waking after sleep onset, and to
consolidate sleep are associated with the α1-subunit [14, 15].
The various side eﬀects associated with benzodiazepines
stimulated the search for alternative compounds for the
treatment of insomnia. Therefore, the goal of this study
was to evaluate the hypnotic eﬀects of the ethanol extract
of the ﬂower of C. morifolium (EFC) on pentobarbital-
induced sleep behaviors and to investigate its possible
mechanisms.
2.MaterialsandMethods
2.1. Animals. Male ICR mice (Samtako, Korea) weighing
20–25g, in groups of 10–12, were used for behavioral
experiments. Animals were housed in acrylic cages (45 ×
60 × 25cm) with water and food available ad libitum under
an artiﬁcial 12-h light/dark cycle (lights on at 7:00) and at
a constant temperature (22 ± 2◦C). Mice were housed in
the departmental room for 1 week before testing to ensure
adaptation to the new environment. All of the behavioral
experiments were performed between 10:00 and 17:00. All
of the experiments involving animals were carried out in
accordance with the National Institutes of Health Guide for
Care and Use of Laboratory Animals (NIH publication No.
85-23, revised 1985), and the Institutional Animal Care and
Use Committee of Chungbuk National University approved
the protocol.
2.2. Cell Culture. Primary cultures of cerebellar neurons
enriched in granule cells were prepared from cerebella of 8-
day-old Sprague-Dawley rats as previously described [16].
After 8 days in culture, these cells express functional GABAA
receptors, with an expression pattern similar to that of
the cerebellum during postnatal development, but diﬀerent
from the pattern observed in the adult rat cerebellum
[17]. Brieﬂy, cells were plated (1 × 105 cells per well)
in 96-well microplates that had been coated with poly-L-
lysine (50μg/mL; Sigma, St. Louis, MO, USA) and were
cultured in Dulbecco’s modiﬁed Eagle’s medium nutrient
and Ham’s F12 mixture media (Life Technologies, Gaithers-
burg, MD, USA) supplemented with 10% heat-inactivated
fetal bovine serum (Life Technologies), glutamine (2mM),
gentamicin (100μg/mL), antibiotic-antimycotic solution
(10mL/L; Sigma) and Potassium chloride (25mM); a
high concentration of potassium was necessary to induce
persistent depolarization, which promotes the survival of
granule cells. Cytosine arabinofuranoside (ﬁnal concen-
tration, 10μM; Sigma) was added to cultures 18–24h
after plating, to inhibit the proliferation of nonneuronal
cells.
2.3. Ethanol Extraction of C. morifolium. The plant materials
were collected during October 2009 at Jiri Mt., Jeonbuk,
Korea. The shade-dried C. morifolium ﬂower (100g) was
extracted three times with 70% EtOH at 50◦C. The extracts
were ﬁltered and concentrated using a rotary vacuum evapo-
rator, followed by lyophilization. The yield of C. morifolium
ﬂ o w e re x t r a c t s( E F C )w a sa p p r o x i m a t e l y2 . 5 % .
2.4. Pentobarbital-Induced Sleep. Pentobarbital sodium
(Hanlim Pharm. Co., Ltd., Korea) was diluted in
physiological saline and administered to each mouse
intraperitoneally (i.p.) to induce sleep. EFC was suspended
in physiological saline and was administered orally (p.o.)
to animals. Muscimol (Sigma, USA) was administered
as a reference drug 15min prior to administration of
pentobarbital. All experiments were carried out between
13:00 and 17:00. Animals were food-deprived for 24h
prior to the experiment. Thirty minutes after the oral
administration of the test samples, pentobarbital was given
to animals placed in a box. Animals that stopped moving
around the box, whereas animals that failed to fall asleep
within 15min after pentobarbital administration were
excluded from the study [18, 19]. Mice that remained
immobile for more than 3min were judged to be asleep. The
time that elapsed from receiving pentobarbital until each
animal lost its righting reﬂex when positioned delicately
on its back represented the latency to onset of sleep.
The animals were observed constantly, and the time of
awakening, characterized by righting of the animal, was
noted. Sleep time was deﬁned as the time required for the
animal to regain spontaneous movements after having been
transferred to the second box.
2.5. Measurement of Intracellular Cl− Inﬂux. The intracel-
lular Cl− concentration ([Cl−]i) of cerebellar granule cells
was estimated using Cl− sensitive ﬂuorescence probe N-
(ethoxycarbonylmethyl)-6-methyoxyquionolinium bromide
(MQAE) according to the method of West and Molloy, with
a slight modiﬁcation [20]. The buﬀer (pH 7.4) contained the
following components: 2.4mM HPO4
2−,0 . 6m MH 2PO4
−,
10mM HEPES, 10mM D-glucose, and 1mM MgSO4.A
variety of MQAE-loading conditions were assessed. The cells
were incubated overnight in medium containing 10mM
MQAE(Dojindo,Japan).Afterloading,thecellswerewashed
three times in the appropriate Cl− containing buﬀer or
Cl−-free buﬀer. The buﬀe rw a sr e p l a c e dw i t hb u ﬀer with
or without the compounds or Cl−-free buﬀer. Repetitive
ﬂuorescence measurements were initiated immediately using
a FLUOstar plate reader (Excitation wavelength: 320nm,
emission wavelength: 460nm; BMG LabTechnology, Ger-
many). The data is presented as the relative ﬂuorescence
F0/F,w h e r eF0 is the ﬂuorescence without Cl− ions and F is
the ﬂuorescence as a function of time. The F0/F values were
directly proportional to [Cl−]i.
2.6. GAD and GABAA Receptors Subunits Expression. Mice
were administered EFC or pentobarbital for 3 days and
sacriﬁced. The mice were decapitated, their brains removed
and the hippocampus dissected on ice according to the
methods described by Glowinski and Iversen [21]a n dS e g a l
and Kuczenski [22]. Mouse hippocampus was homogenized
with lysis buﬀer. The extracts were centrifuged at 20,000×g
for 20min. Equal amounts of proteins were separated on
a 10% SDS/polyacrylamide gel and transferred to a nitro-
cellulose membrane (Hyboud ECL, Amersham Pharmacia
Biotech Inc., Piscataway, NJ, USA). The blots were blockedEvidence-Based Complementary and Alternative Medicine 3
Table 1: Eﬀects of EFC on sleep onset of mice treated by
subhypnotic doses of pentobarbital (28mg/kg, i.p.).
Group Dose
(mg/kg)
No. falling
asleep/total
Sleep time
(min)
Control 0 6/15 23.3 ±1.8
Muscimol 0.2 13/14∗∗ 41.2 ±4.2∗∗∗
EFC 20 7/14 28.0 ±4.0
50 7/14 29.6 ±3.2
100 11/13∗ 35.9 ±3.6∗
Each value represents the mean (±S.E.M.) of 13–15 observations. ∗P<. 05,
∗∗P<. 01, ∗∗∗P<. 005 versus control.
for 2h at room temperature with 5% (w/v) nonfat dried
milkinTris-buﬀeredsalinesolution(10mMTris,pH8.0and
150mM NaCl) containing 0.1% Tween-20. The membrane
was incubated with speciﬁc rabbit polyclonal antibodies
against GABAA receptor subunits (1:1000; Abcam Inc.) for
2h at room temperature. The blot was then incubated with
the corresponding antirabbit IgG-conjugated to horseradish
peroxidase(SantaCruzBiotechnologyInc.).Theimmunore-
active proteins were detected using the ECL western blotting
detection system [23].
2.7. Statistical Analysis. The results are presented as the
mean ± S.E.M. The signiﬁcance of the eﬀects of the com-
pounds was assessed using analysis of variance (ANOVA).
Where there was signiﬁcant variability, the individual values
were compared using Dunnett’s test. For the subhypnotic
pentobarbital dosage experiment, Chi-square test was used
to compare the proportion of sleep onset between the
group treated with a subhypnotic dose of pentobarbital
alone and each of the groups that received pentobarbital in
combination with another drug.
3. Results
3.1. Eﬀects of EFC on the Onset and Duration of Sleep
in Pentobarbital-Treated Mice. The administration of EFC
increased sleep time. EFC produced a dose-dependent
prolongation of pentobarbital-induced sleep time at dose
of 50mg/kg and 100mg/kg; however, EFC did not aﬀect
the latency of sleep. Pretreatment of mice with muscimol
(0.2mg/kg, i.p.) as a positive control, 15min before the
administration of pentobarbital (40mg/kg), produced an
increase in total sleep time and a decrease in the latency of
sleep (Figure 1).
3.2. Eﬀects of EFC on Sleep Onset in Mice Treated with a
Subhypnotic Dosage of Pentobarbital. Administration of EFC
increased the rate of sleep onset and the duration of sleep
time induced by a subhypnotic dosage of pentobarbital
(28mg/kg, i.p.). Pretreatment with muscimol also increased
the rate of sleep onset and prolonged the duration of sleep
time when given in combination with a subhypnotic dosage
(mg/kg) 100 50 20 0.2 CON
EFC Muscimol
0
60
120
∗∗∗
∗∗∗
∗∗∗
Pentobarbital (40mg/kg, i.p.)
S
l
e
e
p
t
i
m
e
(
m
i
n
)
(a)
(mg/kg) 100 50 20 0.2 CON
EFC Muscimol
0
1
2
3
4
5
∗∗∗
∗∗
S
l
e
e
p
l
a
t
e
n
c
y
(
m
i
n
)
(b)
Figure 1: Eﬀects of EFC on onset and duration of sleep in
pentobarbital-treated mice. Mice were food-deprived for 24h
before the experiment. Pentobarbital (40mg/kg, i.p.) was admin-
istered to mice following administration of muscimol or EFC. The
sleep time (a) and sleep latency (b) were recorded. Each column
represents the mean with S.E.M. The signiﬁcance of the eﬀects of
the compounds was assessed using analysis of variance (ANOVA).
∗∗P<. 01, ∗∗∗P<. 005, compared to control.
of pentobarbital (Table 1). EFC showed similar eﬀects to
mucimol at 100mg/kg.
3.3. Eﬀects of EFC on Cl− Inﬂux in Primary Cultured
Cerebellar Granule Cells. Intracellular chloride ion inﬂux in
primary cultured cerebellar granule cells was measured. The
measured data is presented as the relative ﬂuorescence F0/F,
where F0 is the ﬂuorescence without chloride ions and F
is the ﬂuorescence as a function of each sample. The F0/F
values were directly proportional to intracellular chloride
ion concentration. Treatment of granule cells with EFC (1–
4μg/mL) produced a signiﬁcant increase in chloride ion
inﬂux. Pentobarbital 10μM also increased the inﬂux of Cl−
in primary cultured cerebellar granule cells (Figure 2).4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Eﬀects of EFC on chloride inﬂux in primary cultured
cerebellar granule cells. After the culture of cerebellar granule cells
for 8 days, the cells were incubated with MQAE overnight, and then
EFC (1–4μg/mL) and pentobarbital (PENT, 10μM) were added
5min prior to measurement. PENT: pentobarbital. Each column
represents the mean with S.E.M. The signiﬁcance of the eﬀects of
the compounds was assessed using analysis of variance (ANOVA).
∗P<. 05, ∗∗∗P<. 005, compared to control.
3.4. Eﬀects of EFC on Expression of Glutamic Acid Decar-
boxylase (GAD) and Subunit of GABAA Receptor. Mice were
administered 100mg/kg EFC or 40mg/kg pentobarbital for
3 days, and they were sacriﬁced to examine the eﬀect of
thesedrugsontheabundanceofglutamicaciddecarboxylase
(GAD) and GABAA receptor subunits in the hippocampus.
EFC treatment increased expression of GAD65 (Figure 3)b u t
did not inﬂuence the amounts of α1-, β2-, and γ2-subunits
in the GABAA receptor (Figure 4); however, pentobarbital
signiﬁcantly decreased amounts of the α1-subunit, but did
not aﬀect the abundance of β2- and γ2-subunit. Protein
concentrations of GAD65 following pentobarbital treatment
also were not changed.
4. Discussion
The results demonstrate that EFC potentiates pentobarbital-
induced sleep behaviors in mice. The increase and decrease
of pentobarbital-induced sleep time can be a useful tool
for examining the stimulatory or inhibitory eﬀects on
central nervous system (CNS), especially for investigat-
ing drug inﬂuences on GABAergic systems [24, 25]. In
addition, pentobarbital is well known to potentiate the
eﬀects of GABA by acting at its own binding sites on the
GABA/benzodiazepine receptor ionophore complex [25].
Manyhypnotic,antianxietyandantiepilepsydrugshavebeen
shown to cause prolongation of pentobarbital-induced sleep
time [26–28]. We were interested in whether EFC prolongs
pentobarbital-induced sleep behaviors and interacts with
pentobarbital in the CNS via the GABAergic systems.
We investigated the eﬀects of diﬀerent doses of EFC
and muscimol in rodents with pentobarbital treatment. We
foundthatEFCcouldpotentiatepentobarbital-inducedsleep
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Figure 3: Eﬀects of EFC on glutamic acid decarboxylase (GAD).
Immunoblots of lysed mouse hippocampus 3 days following
administration of EFC or pentobarbital are shown. GAPDH
levels were measured to conﬁrm equal protein loading. PENT:
pentobarbital. Each column represents the mean with S.E.M. The
signiﬁcance of the eﬀects of the compounds was assessed using
analysis of variance (ANOVA). ∗P<. 05, compared to control.
at 100mg/kg. Additionally, EFC increased the rate of sleep
onset and prolonged sleep time at subhypnotic dosages of
pentobarbital (28mg/kg). These results are similar to those
of the GABAA receptor agonist muscimol. This indicates
that the hypnotic eﬀect of EFC may be due to interac-
tion with GABAergic systems. GABAA receptors possess
various binding sites, including binding sites for GABA,
benzodiazepine, and barbiturates. GABAA receptors form
heteromeric GABA-gated Cl− channels, which are assembled
from a large family of subunit genes. GABAA receptor
channels open after binding GABA to give a net inward ﬂux
of negative Cl− ions (outward current), hyperpolarizing the
membrane and reducing neuronal ﬁring [29]. Muscimol and
other GABAA receptor agonists that potentiate Cl− inﬂux
also cause potentiation of Cl− inﬂux when administered
with pentobarbital or other agonists [12] .E F Cp r o d u c e da
signiﬁcant increase in Cl− inﬂux; this increase was similar
to that of pentobarbital. This suggests that EFC may act to
induce Cl− channel opening of GABAA receptors.
Researchers have demonstrated that the pharmacological
proﬁle and diﬀerent drug-induced behaviors of GABAA
receptors depend upon its subunit composition [30]. Glu-
tamic acid decarboxylase (GAD), the rate-liminting enzyme
in GABA biosynthesis, also plays an important role in
maintaining GABA levels in the brain [31]. Hence, alteration
of expression levels of this enzyme may change GABA trans-
mission in the brain. We sought to determine GAD protein
andGABAA receptorsubunitexpressionlevelsattheeﬀective
dosage of EFC and pentobarbital to determine the possibleEvidence-Based Complementary and Alternative Medicine 5
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Figure 4: Eﬀects of EFC on GABAA receptor subunits. Immunob-
lotsoflysedmousehippocampus3daysfollowingadministrationof
EFC or pentobarbital are shown. GAPDH levels were measured to
conﬁrm equal protein loading. PENT: pentobarbital. Each column
represents the mean with S.E.M. The signiﬁcance of the eﬀects of
the compounds was assessed using analysis of variance (ANOVA).
∗P<. 05, compared to control.
site of action by which EFC exerts its sleep-potentiating
eﬀects. GAD has two molecular forms (GAD65 and GAD67
with molecular weights of 65kDa and 67kDa, respectively),
and we investigated expression levels of GAD65.G A D 65 is
responsible for vesicular GABA production; therefore this
isoform is directly involved in GABA transmission at the
synapse [32]. We also investigated the expression levels
of GABAA receptor α1-, β2-, and γ2-subunits. The most
abundant GABAA receptor subunit composition, α1β2γ2, is
present in most brain regions, including the hippocampus,
and these subunits are related to the hypnotic/sedative
eﬀect of GABAA receptor ligands [30]. Our results showed
that neither EFC nor pentobarbital treatment inﬂuenced
expression of GABAA receptor β2- and γ2-subunits; however
pentobarbital decreased abundance of α1-subunits, and EFC
increased levels of GAD.
Many herbal preparations and a diversity of drugs used
to promote sleep are known to act on GABAA receptors [33].
Drugs acting on GABAA receptors mainly act to increase
synaptic inhibition either by directly activating GABAA
receptors or, more usually, by enhancing the action of other
ligands on GABAA receptors. Our results suggest that EFC
Glutamate
GABA
GAD
+
EFC
Cl−
GABA level ↑
Cl− inﬂux ↑
Potentiation of
pentobarbital-induced sleep
Figure 5: A proposed mechanism of EFC in augmenting pento-
barbital-induced sleep. EFC administration will increase expression
levels of GAD, the rate-limiting enzyme in GABA biosynthesis,
thereby increasing GABA levels. This will promote Cl− channel
opening, causing hyperpolarization of the post-synaptic neuron.
Hyperpolarization may result in potentiation of pentobarbital-
induced sleep.
has sleep-potentiating eﬀects, which may be mediated by
Cl− channel opening (Figure 5).
The search for novel plant-derived pharmacotherapies
for psychiatric illness has progressed signiﬁcantly in the
past decade. A considerable number of herbal constituents
whose behavioral eﬀects and pharmacological actions have
been well characterized may be good candidates for further
investigations that may ultimately lead to clinical use of these
constituents. The potential beneﬁts of herbal remedies such
as St. John’s wort and Kava-kava in psychiatric practice have
been addressed previously [34]. EFC may be another good
candidate for the treatment of psychiatric illnesses, such as
sleep disorders.
5. Conclusions
E F Ce n h a n c e dh y p n o t i ce ﬀects in pentobarbital-treated
mice. This enhancement may resultfromCl− channel activa-
tion. Further investigation is needed to determine the eﬀects
of other EFC derivatives with strong pharmacological action.
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